IL192349A0 - Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms - Google Patents
Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptomsInfo
- Publication number
- IL192349A0 IL192349A0 IL192349A IL19234908A IL192349A0 IL 192349 A0 IL192349 A0 IL 192349A0 IL 192349 A IL192349 A IL 192349A IL 19234908 A IL19234908 A IL 19234908A IL 192349 A0 IL192349 A0 IL 192349A0
- Authority
- IL
- Israel
- Prior art keywords
- pro
- peptide
- arg
- gly
- pharmaceutical composition
- Prior art date
Links
- 206010049771 Shock haemorrhagic Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 208000024891 symptom Diseases 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 102000009123 Fibrin Human genes 0.000 abstract 3
- 108010073385 Fibrin Proteins 0.000 abstract 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 3
- 102000004889 Interleukin-6 Human genes 0.000 abstract 3
- 108090001005 Interleukin-6 Proteins 0.000 abstract 3
- 229950003499 fibrin Drugs 0.000 abstract 3
- 229940100601 interleukin-6 Drugs 0.000 abstract 3
- 102000000905 Cadherin Human genes 0.000 abstract 2
- 108050007957 Cadherin Proteins 0.000 abstract 2
- 208000032456 Hemorrhagic Shock Diseases 0.000 abstract 2
- 230000004071 biological effect Effects 0.000 abstract 2
- 230000003511 endothelial effect Effects 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 230000035939 shock Effects 0.000 abstract 2
- 230000002792 vascular Effects 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001553 hepatotropic effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0206705A AT502987A1 (de) | 2005-12-23 | 2005-12-23 | Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen |
| PCT/AT2006/000465 WO2007070899A2 (de) | 2005-12-23 | 2006-11-10 | Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL192349A0 true IL192349A0 (en) | 2008-12-29 |
Family
ID=37846035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL192349A IL192349A0 (en) | 2005-12-23 | 2008-06-19 | Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7897574B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1962887B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2009520696A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080108221A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101365477A (cg-RX-API-DMAC7.html) |
| AT (2) | AT502987A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006326890A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2634026A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE502006004619D1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2331970T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL192349A0 (cg-RX-API-DMAC7.html) |
| NO (1) | NO20083191L (cg-RX-API-DMAC7.html) |
| RU (1) | RU2008130413A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007070899A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101389653A (zh) * | 2006-02-23 | 2009-03-18 | 菲布雷克斯医疗研究及开发有限责任公司 | 肽和肽衍生物以及含有它们的药物组合物 |
| EP2193370A2 (en) * | 2007-09-24 | 2010-06-09 | Fibrex Medical Research & Development GmbH | Methods of screening for compounds having anti-inflammatory activity |
| US20130324469A1 (en) * | 2010-12-09 | 2013-12-05 | The Brigham And Women's Hospital, Inc. | Fibrinogen and kidney damage |
| US20170112941A1 (en) * | 2015-10-13 | 2017-04-27 | Symic Ip, Llc | Ve-cadherin binding bioconjugate |
| JP7506364B2 (ja) * | 2019-10-24 | 2024-06-26 | 国立大学法人東海国立大学機構 | 慢性肺疾患／急性呼吸窮迫症候群の治療薬 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5997844A (en) | 1991-02-08 | 1999-12-07 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| CA2430972C (en) | 2000-12-12 | 2014-08-05 | Fibrex Medical Research & Development Gmbh | Fibrin fragments for treating inflammation |
| US20080311103A1 (en) | 2004-03-08 | 2008-12-18 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Anti-Inflammatory Peptides and Methods of Use Thereof |
| AT414097B (de) | 2004-06-25 | 2006-09-15 | Petzelbauer Peter Dr | Pharmazeutische zubereitung zur behandlung von schock |
| WO2006000007A1 (de) | 2004-06-25 | 2006-01-05 | Fibrex Medical Research & Development Gesmbh | Verwendung von peptiden, die aus der a alpha oder der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock |
-
2005
- 2005-12-23 AT AT0206705A patent/AT502987A1/de not_active Application Discontinuation
-
2006
- 2006-11-10 KR KR1020087017988A patent/KR20080108221A/ko not_active Ceased
- 2006-11-10 JP JP2008546020A patent/JP2009520696A/ja active Pending
- 2006-11-10 CA CA002634026A patent/CA2634026A1/en not_active Abandoned
- 2006-11-10 ES ES06804388T patent/ES2331970T3/es active Active
- 2006-11-10 AT AT06804388T patent/ATE440282T1/de active
- 2006-11-10 CN CNA2006800486507A patent/CN101365477A/zh active Pending
- 2006-11-10 AU AU2006326890A patent/AU2006326890A1/en not_active Abandoned
- 2006-11-10 EP EP06804388A patent/EP1962887B1/de active Active
- 2006-11-10 WO PCT/AT2006/000465 patent/WO2007070899A2/de not_active Ceased
- 2006-11-10 RU RU2008130413/15A patent/RU2008130413A/ru not_active Application Discontinuation
- 2006-11-10 US US12/158,670 patent/US7897574B2/en not_active Expired - Fee Related
- 2006-11-10 EP EP09010282A patent/EP2110136A3/de not_active Withdrawn
- 2006-11-10 DE DE502006004619T patent/DE502006004619D1/de active Active
-
2008
- 2008-06-19 IL IL192349A patent/IL192349A0/en unknown
- 2008-07-17 NO NO20083191A patent/NO20083191L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101365477A (zh) | 2009-02-11 |
| JP2009520696A (ja) | 2009-05-28 |
| WO2007070899A2 (de) | 2007-06-28 |
| EP2110136A2 (de) | 2009-10-21 |
| AT502987A1 (de) | 2007-07-15 |
| AU2006326890A1 (en) | 2007-06-28 |
| US7897574B2 (en) | 2011-03-01 |
| DE502006004619D1 (de) | 2009-10-01 |
| KR20080108221A (ko) | 2008-12-12 |
| EP1962887B1 (de) | 2009-08-19 |
| ATE440282T1 (de) | 2009-09-15 |
| CA2634026A1 (en) | 2007-06-28 |
| EP2110136A3 (de) | 2010-01-27 |
| RU2008130413A (ru) | 2010-01-27 |
| WO2007070899A3 (de) | 2007-10-04 |
| NO20083191L (no) | 2008-09-16 |
| ES2331970T3 (es) | 2010-01-21 |
| EP1962887A2 (de) | 2008-09-03 |
| US20090005310A1 (en) | 2009-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL192349A0 (en) | Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms | |
| SE9800836D0 (sv) | New Compounds | |
| WO2004046345A3 (en) | Use of hmgb fragments as anti-inflammatory agents | |
| Chain et al. | Plasmin cleavage of vitronectin Identification of the site and consequent attenuation in binding plasminogen activator inhibitor‐1 | |
| NO20055863L (no) | W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer | |
| IL194843A0 (en) | Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors | |
| UA98585C2 (uk) | Антитіло, яке специфічно зв'язується з нейропіліном-1 (nrp1) | |
| WO2006099261A3 (en) | Potent and specific immunoproteasome inhibitors | |
| AR039103A1 (es) | Uso de inhibidores de il-18 para el tratamiento y/o prevencion de enfermedades vasculares perifericas | |
| NZ593815A (en) | Tissue factor pathway inhibitor (tfpi) inhibitors and methods of use | |
| HUP0402506A2 (hu) | FBPáz inhibitorok és inzulinérzékenység-fokozók kombinációja diabétesz kezelésére | |
| EP2266561A3 (en) | IKK Inhibitors for the Treatment of Endometriosis | |
| WO2005117846A3 (en) | Ice inhibitors for the treatment of autoinflammatory diseases | |
| Wittig et al. | Endothelial-dependent S-Sulfhydration of tissue factor pathway inhibitor regulates blood coagulation | |
| DK1233787T3 (da) | Produkt, der inhiberer signaltransduktion fra heterotrimere G-proteiner, kombineret med et andet cancerbekæmpende middel til terapeutisk anvendelse i cancerbehandlingen | |
| Etscheid et al. | The hyaluronan-binding protease upregulates ERK1/2 and PI3K/Akt signalling pathways in fibroblasts and stimulates cell proliferation and migration | |
| Ha et al. | Nox4-dependent H2O2 production contributes to chronic glutamate toxicity in primary cortical neurons | |
| DK2089433T3 (da) | Behandling, der er rettet mod cathepsin S | |
| ATE289319T1 (de) | Dipeptidische hemmstoffe für den gerinnungsfaktor xa | |
| NO20080781L (no) | GLEPP-inhibitorer i behandlingen av autoimmune og/eller inflammatoriske sykdommer | |
| EA200600561A1 (ru) | Фармацевтический препарат для лечения шока | |
| DK0833848T3 (da) | Faktor IX-bindende peptider afledt af faktor VIII og anvendelse heraf som inhibitorer af blodkoagulation | |
| ATE556134T1 (de) | Mesenchymstammzellen und verwendungendafür | |
| EA200300572A1 (ru) | Комбинированная терапия эстроген-зависимых заболеваний | |
| BRPI0616535B8 (pt) | uso de fator de tecido (tf) lipidado ou um fragmento funcional do mesmo, produto, uso de um produto, complexo (tf::fxa), uso de um complexo, complexo tf::ncis, complexo tf::fxa:ncis, composição farmacêutica e uso de tf não-lipidado ou um fragmento funcional do mesmo |